The authors estimate that 24% (lower bound), 56% (mid-range) and 62% (upper bound) of US patients with major depressive disorder or treatment-resistant depression would be eligible for psilocybin-assisted therapy under different exclusion scenarios. They find that exclusionary comorbidities—particularly substance and alcohol use disorders and overlapping psychiatric or cardiovascular conditions—drive most ineligibility, and that real demand will hinge on insurance, state regulation and provider availability.
- Published
- Journal
- Psychedelics
- Authors
- Rab, S. F., Raison, C. L., Marseille, E.